login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Account
Disclaimer
Affiliate
Contact
Privacy
DR. REDDY'S LABORATORIES-ADR (RDY) Stock News
USA
- NYSE:RDY -
US2561352038
-
ADR
14.6
USD
-0.27 (-1.82%)
Last: 9/22/2025, 8:04:00 PM
14.6
USD
0 (0%)
After Hours:
9/22/2025, 8:04:00 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
RDY Latest News, Press Relases and Analysis
All
Press Releases
21 days ago - By: Chartmill
Dr. Reddy's Laboratories (NYSE:RDY): A Peter Lynch-Style GARP Investment
14 days ago - By: Zacks Investment Research
- Mentions:
TEVA
ALVO
ALVO Stock Trades Near 52-Week Low: Should You Buy, Hold or Sell?
2 months ago - By: Dr. Reddy’s Laboratories Ltd.
Dr. Reddy’s Q1FY26 Financial Results
2 months ago - By: Yahoo Finance
- Mentions:
ALVO
Dr. Reddy’s Laboratories (RDY) and Alvotech Enter Into a Collaboration and License Agreement
4 months ago - By: Yahoo Finance
- Mentions:
JPM
RELI
OMI
SMLR
...
JPMorgan Backs RIL Despite Margin Pressures
4 months ago - By: Yahoo Finance
- Mentions:
OMI
SMLR
RNXT
HUM
...
Owens & Minor and Rotech Healthcare Agree to End Previously Planned Acquisition
4 months ago - By: Benzinga
- Mentions:
JNJ
MRK
ALVO
Dr Reddy's And Alvotech Join Hands To Develop Biosimilar For Merck's Blockbuster Cancer Drug
4 months ago - By: Zacks Investment Research
- Mentions:
MRK
AMGN
ALVO
RDY & ALVO Ink Collaboration Deal for Merck's Keytruda Biosimilar
4 months ago - By: Dr. Reddy’s Laboratories Ltd.
- Mentions:
ALVO
Alvotech and Dr. Reddy’s Enter into Collaboration to Co-Develop Biosimilar Candidate to Keytruda® (pembrolizumab)
4 months ago - By: Alvotech
- Mentions:
ALVO
SDB
Alvotech and Dr. Reddy’s Enter into Collaboration to Co-Develop Biosimilar Candidate to Keytruda® (pembrolizumab)
4 months ago - By: Zacks Investment Research
- Mentions:
ALLO
ALVO
RDY Q4 Earnings Beat Estimates, Generics Revenues Rise Y/Y, Stock Up
5 months ago - By: Dr. Reddy’s Laboratories Ltd.
Dr. Reddy’s Q4 & Full Year FY25 Financial Results
5 months ago - By: Zacks Investment Research
- Mentions:
TEVA
3 Generic Drug Stocks to Watch Amid Trade War Jitters & Inflation Woes
5 months ago - By: Yahoo Finance
- Mentions:
AAPL
MSFT
Dr. Reddy’s Laboratories (RDY): Among the Best Indian Stocks to Buy According to Billionaires
6 months ago - By: Benzinga
- Mentions:
ARGX
GILD
REGN
AZN
...
Pharma Industry Faces Jitters As Trump Hints At Historic Tariffs, BofA Outlines Probable Timeline
6 months ago - By: Zacks Investment Research
- Mentions:
JNJ
AMGN
ALVO
RDY & Bio-Thera Ink Deal for JNJ's Stelara/Simponi Biosimilar
6 months ago - By: Bio-Thera Solutions, Ltd
Bio-Thera and Dr. Reddy's Execute Exclusive Commercialization Agreement for BAT2206, a Proposed Stelara® Biosimilar, and BAT2506, a Proposed Simponi® Biosimilar, for Southeast Asia
6 months ago - By: Dr. Reddy’s Laboratories Ltd.
- Mentions:
ALVO
Alvotech and Dr. Reddy’s Announce FDA Acceptance of Biologic License Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®
6 months ago - By: Alvotech
- Mentions:
ALVO
Alvotech and Dr. Reddy’s Announce FDA acceptance of Biologic License Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®
6 months ago - By: Dr. Reddy’s Laboratories Ltd.
Dr. Reddy's Issues a Nationwide Recall of Levetiracetam in 0.75% Sodium Chloride Injection 1,000 mg/100 mL, in the U.S., due to Mislabeling of Infusion Bag
8 months ago - By: Henlius
Henlius und Dr. Reddy's unterzeichnen Lizenzvertrag für HLX15 (Daratumumab-Biosimilar) zur Expansion in Europa und den USA
8 months ago - By: Henlius
Henlius y Dr. Reddy's firman un acuerdo de licencia para la expansión de HLX15 en Europa y EE.UU.
8 months ago - By: Henlius
Henlius et Dr. Reddy's signent un accord de licence pour l'expansion de HLX15 (biosimilaire expérimental du daratumumab) en Europe et aux États-Unis.
8 months ago - By: Dr. Reddy’s Laboratories Ltd.
Dr. Reddy’s enters into collaboration with Henlius for commercialization of HLX15 (daratumumab), a biosimilar candidate to Darzalex® & Darzalex Faspro® in the U.S., and Europe
8 months ago - By: Henlius
Henlius and Dr. Reddy's Ink Licensing Deal for HLX15 (investigational daratumumab biosimilar) Expansion in Europe and the U.S.
Please enable JavaScript to continue using this application.